pharma.be supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.
PB
pharma.be
Industry association · Belgium · EU Transparency Register 25571625843-29
5
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #718 by legislative files engaged, a count of participation, not a measure of influence.
1.5
declared lobbying FTE
self-declared
€400K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- pharma.be is lid van EFPIA, de Europese geneesmiddelenfederatie.
- pharma.be is lid van IFPMA, de Internationale Federatie van Farmaceutische Producenten en Associaties
- pharma.be is lid van AESGP, Association of the European Self-Medication Industry
- pharma.be is lid van Animal Health Europe
- de vereniging die de fabrikanten van diergeneesmiddelen
- vaccins en andere diergezondheidsproducten in Europa vertegenwoordigt
- pharma.be is lid van Health for Animals, deze vereniging vertegenwoordigt de sector diergezondheid: fabrikanten van g…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade and business associations
- Registered as
- Algemene vereniging van de Geneesmiddelenindustrie (pharma.be)
- Head office
- Brussel, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track pharma.be in PolicySpeak: request access →
Work at pharma.be? so we know who speaks for it.
Their record over time
pharma.be filed 5 positions between 5 Jan 2021 and 10 Jun 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 2 filed2023 · 1 filed2025 · 1 filed2026 · 1 filed
What they argued
Together with EFPIA, pharma.be supports an agile regulatory framework and a strong incentives’ system that embrace and encourage advances in science, technology and medicines. This evaluation is an opportunity to implement learnings from COVID-19 and ensure a competitive, world-class regulatory system in Europe supporting a globally competitive research-based industry at a critical time.
Response of pharma.be to the Call for Evidence on the Biotech Act Pharma.be strongly supports the ambition to foster a world-class innovation environment for biotechnologies. To make the EU more attractive for researching, developing and manufacturing new technologies, simplify and safeguard a robust IP framework.
The competitiveness level of the biopharma sector has only deteriorated recently. The General Pharmaceutical Legislation (GPL) represents a clear step backwards in terms of regulatory environment for the development of innovative medicines (notably regarding IP-protection).
About 500.000 patients are suffering from rare diseases (RD) in Belgium. The EU Orphan Regulation has highly incentivized pharmaceutical industries to develop new treatments for those patients. The number of clinical trials in RD in Belgium has increased by 13% over the past 4 years; more than 20% of the clinical trials running today are in RD.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put pharma.be next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 166.
Is this your organization?
Everything on this page comes from pharma.be’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.